Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1995 Mar;15(2):61-8.
doi: 10.1007/BF01541733.

HIV-mediated B-lymphocyte activation and lymphomagenesis

Affiliations
Review

HIV-mediated B-lymphocyte activation and lymphomagenesis

J G Monroe et al. J Clin Immunol. 1995 Mar.

Abstract

Non-Hodgkin's (1ii)lymphoma is an AIDS-defining event in a significant percent of U.S. patients infected with the human immunodeficiency virus (HIV). Advances in anti-retroviral treatment and management of opportunistic infection have been accompanied by an increase in the incidence of these lymphomas. In the immunocompromised state of patients late in the course of HIV infection, these lymphomas represent a complication of HIV infection that is associated with an extremely poor prognosis. Currently, there is little understanding of the pathogenesis of HIV-associated lymphomas, which are nearly exclusively of B-cell origin. Experimental data do not support HIV infection in these lymphomas. While some lymphomas show evidence of EBV infection, the majority do not. Polyclonal B-cell hyperactivity during the early phases of HIV infection argues that chronic B-cell stimulation may be the major process predisposing B-cells in the HIV-infected individual to malignant transformation. The mechanism of this stimulation of normal B cells and its relationship to AIDS-associated lymphomas remain poorly understood. In this review, we will summarize current information on HIV-associated B lymphoma and then discuss our views on the association and regulation of HIV-related hyperactivity on the pathogenesis of this lymphoma.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Proc Natl Acad Sci U S A. 1985 Dec;82(23):8198-202 - PubMed
    1. Eur J Immunol. 1992 Nov;22(11):2937-42 - PubMed
    1. Lancet. 1991 Oct 5;338(8771):884-5 - PubMed
    1. J Exp Med. 1990 Oct 1;172(4):1151-8 - PubMed
    1. JAMA. 1986 Jul 25;256(4):491-3 - PubMed

MeSH terms

LinkOut - more resources